Dynavax Technologies Stock Price. Everything You Need To Know About The Dynavax Technologies Stock!
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. The company is headquartered in Emeryville, California and currently employs 351 full-time employees. The company went IPO on 2004-02-19. The firm’s products include HEPLISAV-B vaccine and CpG 1018. Its HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. The company also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. The firm is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. The company is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, which are focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza, and universal influenza.
Dynavax Technologies Stock Price. Everything You Need To Know About The Dynavax Technologies Stock! performance
- Employees 351
- Company HQ Emeryville
- Website https://www.dynavax.com/
- DVAX Asset Type Common Stock
- DVAX Market Capitalization 1.5B
- Earnings Per Share -0.05
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth -0.765
Dynavax Technologies is a promising stock investment option for retail investors from Malaysia, Thailand, Indonesia, and Vietnam. As a biopharmaceutical company, Dynavax specializes in developing innovative vaccines to combat infectious diseases and other serious healthcare conditions. With a focus on immunotherapy and personalized medicine, Dynavax has gained significant traction in the healthcare sector and has shown tremendous growth potential. To invest in Dynavax Technologies from Malaysia, Thailand, Indonesia, or Vietnam, retail investors can utilize Zorion’s user-friendly investment platform. Zorion provides real-time insights and comprehensive recommendations to help investors make informed decisions about their investments. Retail investors can also benefit from the vast array of educational resources and materials available on Zorion, empowering them to enhance their investment knowledge. Investing in Dynavax Technologies through Zorion offers an excellent opportunity for retail investors looking to diversify their portfolio and tap into the potential of the biopharmaceutical market. With Zorion’s seamless investment experience and Dynavax’s bright future, retail investors can confidently venture into this promising stock from Southeast Asia.
